Lundbeck Seattle BioPharmaceuticals, Inc.

Lundbeck Seattle BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercialized therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. Its product includes, eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Lundbeck Seattle BioPharmaceuticals, Inc. was formerly known as Alder Biopharmaceuticals, Inc. and changed its name to Lundbeck Seattle BioPharmaceuticals, Inc. in November 2019. The company was founded in 2002 and is based in Bothell, Washington. As of October 22, 2019, Lundbeck Seattle BioPharmaceuticals, Inc. operates as a subsidiary of H. Lundbeck A/S.